Skip to content

Aura Biosciences, Inc. AURA Other income, net (Note 6)

Other income, net (Note 6) at other companies

CG Oncology logo
CG OncologyCGON
-$101K-2,120%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$12K+76.0%
Nuvation Bio logo
Nuvation BioNUVB
$562.75K+2,165%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Merck & Co. logo
Merck & Co.MRK
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s other income, net (note 6)?
Aura Biosciences, Inc. (AURA) reported other income, net (note 6) of $2K in Q1 2026.
How has Aura Biosciences, Inc.'s other income, net (note 6) changed year-over-year?
Aura Biosciences, Inc.'s other income, net (note 6) increased by 108.3% year-over-year, from -$24K to $2K.
What is the long-term trend for Aura Biosciences, Inc.'s other income, net (note 6)?
Over 2 years (2023 to 2025), Aura Biosciences, Inc.'s other income, net (note 6) has grown at a 0.0% compound annual growth rate (CAGR), from -$76K to $76K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.